Organovo Collaborates With MCRI and Leiden University Medical Center to Develop Stem Cell-Based Bioprinted Tissue Treatments for Kidney Disease
Organovo Holdings, Inc. (ONVO)
NASDAQ:AMEX Investor Relations:
organovo.com/about/contact/investor-relations
Company Research
Source: GlobeNewswire
SAN DIEGO, May 30, 2019 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious diseases, today announced a collaboration with Professor Melissa Little at the Murdoch Children's Research Institute (“MCRI”), The Royal Children’s Hospital, Melbourne, Australia and Ton Rabelink at Universiteit Leiden (“LUMC”), Leiden, Netherlands. The project will expand the use of 3D bioprinted stem cell-based therapeutic tissues to applications aimed at treating end-stage renal disease. This multi-organizational effort integrates Organovo’s leading bioprinting platform with MCRI’s advanced stem cell differentiation technology and LUMC’s cell lines and clinical expertise. The collaboration has been made possible through generous funding from Stem Cells Australia and CSL Limited. “Partnerships with world-class institutions can accelerate groundbreaking work in finding cure
Show less
Read more
Impact Snapshot
Event Time:
ONVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONVO alerts
High impacting Organovo Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
ONVO
News
- Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Organovo's fatty liver disease drug meets main goal in mid-stage study [Reuters]Reuters
- Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo [Financial Post (Toronto, Ontario, Canada)Financial Post
- Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo [Yahoo! Finance]Yahoo! Finance
ONVO
Sec Filings
- 5/1/24 - Form 8-K
- 4/30/24 - Form S-1/A
- 4/23/24 - Form 8-K
- ONVO's page on the SEC website